Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00178425 · ClinicalTrials.gov registry record · Phase 4
PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients
A Phase 4 study of Transplantation, Liver, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00178425 is a Phase 4 study of Transplantation, Liver that has completed, run by University of Rochester. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00178425, a Phase 4 study of Transplantation, Liver, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to measure the amount of MMF and tacrolimus concentration in the blood at a given time. Currently MMF is ordered as a set dose and tacrolimus is given based on body weight. While the deceased donor transplant receives the complete liver, in the live donor just over half of the liver is given (about 60%). The way these different types of transplants break down drugs could be different. Measuring the drug levels allows us to know what happens to the medication in between the morning and the evening dose.
Conditions Studied
Interventions
- PROCEDURE Serial blood sampling as described in protocol
- PROCEDURE Estimation of Creatinine Clearance at regular intervals
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00178425
The ClinicalTrials.gov registry entry for NCT00178425 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transplantation, Liver appearing as the primary indexed condition, and to 2 interventions - of which Serial blood sampling as described in protocol is the first listed.
NCT00178425 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00178425 about?
NCT00178425 is a clinical study titled "PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients". The purpose of this study is to measure the amount of MMF and tacrolimus concentration in the blood at a given time. Currently MMF is ordered as a set dose and tacrolimus is given based on body weight. While the deceased donor transplant receives the complete liver, in the live donor just over half ...
What is the current status of trial NCT00178425?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2005-01. Estimated completion is 2006-06.
What conditions does trial NCT00178425 study?
This clinical trial studies the following conditions: Transplantation, Liver.
What interventions are being tested in trial NCT00178425?
The interventions under investigation include: Serial blood sampling as described in protocol (PROCEDURE), Estimation of Creatinine Clearance at regular intervals (PROCEDURE).
Who is sponsoring clinical trial NCT00178425?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00178425 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transplantation, Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.